Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups

K. L. Swanson, R. H. Wiesner, Scott Nyberg, C. B. Rosen, Michael Joseph Krowka

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

To determine the natural history of portopulmonary hypertension (POPH), a retrospective screening-right heart catheterization-survival analysis of patients was performed. We categorized patients by three treatment subgroups: (1) no therapy for pulmonary hypertension (PH) or liver transplantation (LT), (2) therapy for PH alone and (3) therapy for PH followed by LT. Seventy-four patients were identified between 1994 and 2007. Nineteen patients received no therapy for PH and no LT representing the natural history of POPH. Five-year survival was 14%, and 54% had died within 1 year of diagnosis. Five-year survival in 43 patients receiving therapy for PH but no LT was 45%, and 12% had died within 1 year of diagnosis. Twelve patients underwent LT and 5-year survival for the nine receiving therapy for PH was 67% versus 25% in the three who were not pretreated with prostacyclin therapy. The survival of untreated patients with POPH was poor. Subgroups of patients selected to medical treatment with or without LT had better long-term survival. Mortality did not correlate with baseline hemodynamic variables, type of liver disease or severity of hepatic dysfunction. Medical therapy for POPH should be considered in all patients with POPH, but the treatment effects and impact on those considered for LT still requires well-designed, prospective study before practice guidelines can be suggested.

Original languageEnglish (US)
Pages (from-to)2445-2453
Number of pages9
JournalAmerican Journal of Transplantation
Volume8
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

Hypertension
Liver Transplantation
Survival
Pulmonary Hypertension
Therapeutics
Lung Transplantation
Epoprostenol
Cardiac Catheterization
Survival Analysis
Natural History
Practice Guidelines
Liver Diseases
Hemodynamics
Prospective Studies
Mortality
Liver

Keywords

  • Liver transplantation
  • Portal hypertension
  • Pulmonary hypertension
  • Right heart catheterization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)
  • Transplantation

Cite this

Survival in portopulmonary hypertension : Mayo Clinic experience categorized by treatment subgroups. / Swanson, K. L.; Wiesner, R. H.; Nyberg, Scott; Rosen, C. B.; Krowka, Michael Joseph.

In: American Journal of Transplantation, Vol. 8, No. 11, 11.2008, p. 2445-2453.

Research output: Contribution to journalArticle

@article{1bd8b9f901fa43fb81a1aff902b4099c,
title = "Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups",
abstract = "To determine the natural history of portopulmonary hypertension (POPH), a retrospective screening-right heart catheterization-survival analysis of patients was performed. We categorized patients by three treatment subgroups: (1) no therapy for pulmonary hypertension (PH) or liver transplantation (LT), (2) therapy for PH alone and (3) therapy for PH followed by LT. Seventy-four patients were identified between 1994 and 2007. Nineteen patients received no therapy for PH and no LT representing the natural history of POPH. Five-year survival was 14{\%}, and 54{\%} had died within 1 year of diagnosis. Five-year survival in 43 patients receiving therapy for PH but no LT was 45{\%}, and 12{\%} had died within 1 year of diagnosis. Twelve patients underwent LT and 5-year survival for the nine receiving therapy for PH was 67{\%} versus 25{\%} in the three who were not pretreated with prostacyclin therapy. The survival of untreated patients with POPH was poor. Subgroups of patients selected to medical treatment with or without LT had better long-term survival. Mortality did not correlate with baseline hemodynamic variables, type of liver disease or severity of hepatic dysfunction. Medical therapy for POPH should be considered in all patients with POPH, but the treatment effects and impact on those considered for LT still requires well-designed, prospective study before practice guidelines can be suggested.",
keywords = "Liver transplantation, Portal hypertension, Pulmonary hypertension, Right heart catheterization",
author = "Swanson, {K. L.} and Wiesner, {R. H.} and Scott Nyberg and Rosen, {C. B.} and Krowka, {Michael Joseph}",
year = "2008",
month = "11",
doi = "10.1111/j.1600-6143.2008.02384.x",
language = "English (US)",
volume = "8",
pages = "2445--2453",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Survival in portopulmonary hypertension

T2 - Mayo Clinic experience categorized by treatment subgroups

AU - Swanson, K. L.

AU - Wiesner, R. H.

AU - Nyberg, Scott

AU - Rosen, C. B.

AU - Krowka, Michael Joseph

PY - 2008/11

Y1 - 2008/11

N2 - To determine the natural history of portopulmonary hypertension (POPH), a retrospective screening-right heart catheterization-survival analysis of patients was performed. We categorized patients by three treatment subgroups: (1) no therapy for pulmonary hypertension (PH) or liver transplantation (LT), (2) therapy for PH alone and (3) therapy for PH followed by LT. Seventy-four patients were identified between 1994 and 2007. Nineteen patients received no therapy for PH and no LT representing the natural history of POPH. Five-year survival was 14%, and 54% had died within 1 year of diagnosis. Five-year survival in 43 patients receiving therapy for PH but no LT was 45%, and 12% had died within 1 year of diagnosis. Twelve patients underwent LT and 5-year survival for the nine receiving therapy for PH was 67% versus 25% in the three who were not pretreated with prostacyclin therapy. The survival of untreated patients with POPH was poor. Subgroups of patients selected to medical treatment with or without LT had better long-term survival. Mortality did not correlate with baseline hemodynamic variables, type of liver disease or severity of hepatic dysfunction. Medical therapy for POPH should be considered in all patients with POPH, but the treatment effects and impact on those considered for LT still requires well-designed, prospective study before practice guidelines can be suggested.

AB - To determine the natural history of portopulmonary hypertension (POPH), a retrospective screening-right heart catheterization-survival analysis of patients was performed. We categorized patients by three treatment subgroups: (1) no therapy for pulmonary hypertension (PH) or liver transplantation (LT), (2) therapy for PH alone and (3) therapy for PH followed by LT. Seventy-four patients were identified between 1994 and 2007. Nineteen patients received no therapy for PH and no LT representing the natural history of POPH. Five-year survival was 14%, and 54% had died within 1 year of diagnosis. Five-year survival in 43 patients receiving therapy for PH but no LT was 45%, and 12% had died within 1 year of diagnosis. Twelve patients underwent LT and 5-year survival for the nine receiving therapy for PH was 67% versus 25% in the three who were not pretreated with prostacyclin therapy. The survival of untreated patients with POPH was poor. Subgroups of patients selected to medical treatment with or without LT had better long-term survival. Mortality did not correlate with baseline hemodynamic variables, type of liver disease or severity of hepatic dysfunction. Medical therapy for POPH should be considered in all patients with POPH, but the treatment effects and impact on those considered for LT still requires well-designed, prospective study before practice guidelines can be suggested.

KW - Liver transplantation

KW - Portal hypertension

KW - Pulmonary hypertension

KW - Right heart catheterization

UR - http://www.scopus.com/inward/record.url?scp=53749103602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53749103602&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2008.02384.x

DO - 10.1111/j.1600-6143.2008.02384.x

M3 - Article

C2 - 18782292

AN - SCOPUS:53749103602

VL - 8

SP - 2445

EP - 2453

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 11

ER -